These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 15832733)
1. [Preliminary results of neoadjuvant treatment of adenocarcinoma of the gastro-esophageal junction]. Pedrazzani C; Pasini F; Giacopuzzi S; Bernini M; Gabbani M; Grandinetti A; Tomezzoli A; Ruzzenente A; Guglielmi A; de Manzoni G Chir Ital; 2005; 57(1):9-14. PubMed ID: 15832733 [TBL] [Abstract][Full Text] [Related]
2. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843 [TBL] [Abstract][Full Text] [Related]
3. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861 [TBL] [Abstract][Full Text] [Related]
4. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680 [TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. Thuss-Patience PC; Hofheinz RD; Arnold D; Florschütz A; Daum S; Kretzschmar A; Mantovani-Löffler L; Bichev D; Breithaupt K; Kneba M; Schumacher G; Glanemann M; Schlattmann P; Reichardt P; Gahn B Ann Oncol; 2012 Nov; 23(11):2827-2834. PubMed ID: 22734012 [TBL] [Abstract][Full Text] [Related]
6. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study. Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792 [TBL] [Abstract][Full Text] [Related]
7. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M; Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164 [TBL] [Abstract][Full Text] [Related]
8. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424 [TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma. van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156 [TBL] [Abstract][Full Text] [Related]
16. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Ozdemir N; Abali H; Vural M; Yalcin S; Oksuzoglu B; Civelek B; Oguz D; Bostanci B; Yalcin B; Zengin N Cancer Chemother Pharmacol; 2014 Dec; 74(6):1139-47. PubMed ID: 25234436 [TBL] [Abstract][Full Text] [Related]
17. Benefit of neoadjuvant chemotherapy for Siewert type II esophagogastric junction adenocarcinoma. Hosoda K; Yamashita K; Katada N; Moriya H; Mieno H; Sakuramoto S; Kikuchi S; Watanabe M Anticancer Res; 2015 Jan; 35(1):419-25. PubMed ID: 25550582 [TBL] [Abstract][Full Text] [Related]
18. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271 [TBL] [Abstract][Full Text] [Related]
19. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]